title: Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine.
abstract: In 16 patients with documented coronary artery disease, the extent and duration of acute antiischemic and hemodynamic effects of monotherapies with 120 mg of sustained-release isosorbide dinitrate once daily and 8 mg of sustained-release molsidomine 3 times daily were compared according to a randomized, double-blind, cross-over and placebo-controlled protocol including exercise testing for assessment of ST-segment depression (ST) at an identical workload and determination of plasma concentrations of both substances. Up to 8 h after dosing in the morning, more marked and sustained effects were observed with the nitrate (ST at 2 h, -82%; p < 0.001; at 8 h, -64%; p < 0.01) than with molsidomine (2 h, -68%; p < 0.001; at 8 h, -9%; NS). At 12 h, no more meaningful actions were detectable with isosorbide dinitrate (-13%, NS) despite plasma concentrations still within a range otherwise considered therapeutically effective, whereas with molsidomine, at 4 h after renewed dosing, this parameter was reduced by 38% (p < 0.01). However, therapeutic coverage over a 24-h period could be demonstrated on neither regimen, in the case of the nitrate because of the development of early tolerance, and in the case of molsidomine with its meaningfully shorter half-life because of the necessity of increasing the dosing frequency even further. No meaningful adverse effects were observed with either regimen. Nonresponders, overall a minority on one treatment, responded completely to the alternative regimen and vice versa.
authors.affiliation: Deutsches Herzzentrum München, Klinik an der Technischen Universität, Munich, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Lehmann
authors.forename: G
authors.initials: G
authors.lastname: Reiniger
authors.forename: A
authors.initials: A
authors.lastname: Beyerle
authors.forename: A
authors.initials: A
authors.lastname: Schömig
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004311:Double-Blind Method; D005080:Exercise Test; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007548:Isosorbide Dinitrate / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008981:Molsidomine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D014665:Vasodilator Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
chemical_list: D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D008981:Molsidomine; D007548:Isosorbide Dinitrate